FINHUB Insights

MDT · Q3 FY26 · Jan 23, 2026

Medtronic Q3 FY26: where the revenue came from and where it went

Medtronic Q3 FY26: revenue $9B (+9% year over year). Net profit $1.1B. Largest cohort Cardiovascular $3.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jan 23, 2026
Reported
Feb 24, 2026 10-Q
Sankey diagram of Medtronic's income statement for Q3 FY26: revenue of $9 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$9B +9% year over year
Gross profit$5.8B 64% margin
Operating profit$1.5B 16% margin
Net profit$1.1B 13% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jan 23, 2026).
ItemValueShare of revenueYear over year
Revenue 9 100% +9%
Cardiovascular 3.5 39% +14%
Neuroscience Group 2.6 29% +4%
Medical Surgical 2.2 24% +5%
Diabetes Group 0.8 9% +15%
Cost of revenue−3.337%
Gross profit5.864% margin−3pp
SG&A−333%+0pp
Other−1.315%+0pp
Operating profit1.516% margin−4pp
Tax−0.3
Interest & other costs−0.1
Net profit1.113%−3pp
Filing on EDGAR More quarters of MDT

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters